SOUTH SAN FRANCISCO, Calif. — Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced Piro Lito, M.D., Ph.D., associate member and attending physician at Memorial Sloan Kettering Cancer Center (MSK), has joined its scientific advisory board.

“We are thrilled to have Dr. Lito join our scientific advisory board, comprised of industry leaders in oncology, drug development and discovery research,” said Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO. “Dr. Lito is a world-renowned physician-scientist investigating KRAS mutations and their impact on intracellular signaling and cellular function. We look forward to working with him as we move our lead program, a dual inhibitor of inactive and activated KRAS^G12C, towards clinical candidate selection.” 

Dr. Lito’s research focuses on proteins that drive cancer cell growth aiming to uncover the fundamental processes that govern tumor biology and to identify novel therapies that prolong survival and improve the quality of life in patients with cancer. More specifically, his research has made several key contributions in the effort to better understand KRAS-driven cancers and to develop therapeutics that directly target mutant KRAS. Dr. Lito’s laboratory also examines the heterogeneity that exists within cells in a tumor and combines single-cell sequencing methods along with biosensor technologies to map how different tumor populations respond to therapy, potentially leading to an understanding of varying responses to cancer treatment. Dr. Lito obtained his Ph.D. in Biochemistry and Molecular Biology and his M.D. at Michigan State University. He completed his residency in internal medicine at the Beth Israel Deaconess Medical Center at Harvard Medical School, and his fellowship in medical oncology at MSK. Dr. Lito is board certified in internal medicine and medical oncology.

Dr. Lito added, “Frontier aims to develop drugs targeting some of the most important proteins for cancer cell growth and has the potential to make an impact in cancer care. We know that KRAS regularly switches between the activated and inactive states. Blocking both of these states could be an important innovation in the care of patients whose tumors harbor a KRAS mutation. I look forward to collaborating on these programs.”

About Frontier Medicines

Frontier Medicines is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. The company is deploying its technologies in chemoproteomics, covalent drug discovery, and machine learning to potentially develop groundbreaking medicines for genetically-defined patient populations, starting in cancer. Frontier is advancing its wholly-owned pipeline of precision medicines against the most important drivers of cancer. The company’s lead program is focused on KRAS^G12C and is distinct in that it targets direct inhibition of both the activated and inactive forms of KRAS^G12C. This KRAS mutation is found most prevalently in patients with non-small cell lung, colorectal, and pancreatic cancers. For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter.